Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are currently widely used in many types of cancer. However, some patients could not benefit from ICIs. In addition, a standardized biomarker for predicting the efficacy of ICIs is currently unavailable. Thus, we determined whether peripheral blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hye Ryeon, Kang, Jung Hun, Kim, Sung Hyun, Kim, Seung Tae, Kim, Ilhwan, Min, Young Joo, Shin, Seong Hoon, Oh, Sung Yong, Lee, Gyeong-Won, Lee, Ji Hyun, Ji, Jun Ho, Huh, Seok Jae, Lee, Suee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315861/
https://www.ncbi.nlm.nih.gov/pubmed/35884501
http://dx.doi.org/10.3390/cancers14143440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315861/
https://www.ncbi.nlm.nih.gov/pubmed/35884501
http://dx.doi.org/10.3390/cancers14143440

Ejemplares similares